Abstract
Granulocyte colony-stimulating factor (G-CSF) was administered by continuous subcutaneous infusion to 15 patients with non-myeloid malignancies treated by high-dose chemotherapy and autologous bone marrow infusion. G-CSF was given at variable dosage based on neutrophil count. Sustained serum levels of G-CSF were achieved. Neutrophil recovery was accelerated in G-CSF treated patients compared with 18 historical controls and exceeded 0.5 x 10(9)/l at a mean of 11 days after marrow infusion compared with 20 days for controls, a significant difference. This reduction led to significantly fewer days of parenteral antibiotic therapy, 11 versus 18 days in controls, and less isolation in reverse-barrier nursing, 10 versus 18 days.
Publication types
-
Clinical Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Agranulocytosis
-
Bone Marrow Examination
-
Bone Marrow Transplantation / methods*
-
Busulfan / administration & dosage*
-
Busulfan / therapeutic use
-
Clinical Trials as Topic
-
Colony-Stimulating Factors / adverse effects
-
Colony-Stimulating Factors / blood
-
Colony-Stimulating Factors / pharmacology*
-
Combined Modality Therapy
-
Cyclophosphamide / administration & dosage*
-
Cyclophosphamide / therapeutic use
-
Drug Administration Schedule
-
Drug Evaluation
-
Granulocyte Colony-Stimulating Factor
-
Hodgkin Disease / blood
-
Hodgkin Disease / therapy*
-
Humans
-
Infusion Pumps
-
Infusions, Parenteral
-
Leukocyte Count / drug effects
-
Lymphoma, Non-Hodgkin / blood
-
Lymphoma, Non-Hodgkin / therapy*
-
Neoplasms, Germ Cell and Embryonal / blood
-
Neoplasms, Germ Cell and Embryonal / therapy*
-
Neutropenia / chemically induced
-
Neutropenia / drug therapy*
-
Recombinant Proteins / pharmacokinetics
-
Time Factors
Substances
-
Colony-Stimulating Factors
-
Recombinant Proteins
-
Granulocyte Colony-Stimulating Factor
-
Cyclophosphamide
-
Busulfan